StockNews.AI
MGRM
StockNews.AI
112 days

CORRECTION FROM SOURCE: Monogram Technologies Receives Regulatory Approval to Start Clinical Trials in India

1. Monogram received regulatory approval to import mBôs TKA system for clinical trials. 2. Patient enrollment will start soon with surgeries expected in 90 business days.

2m saved
Insight
Article

FAQ

Why Bullish?

Regulatory approval usually boosts investor confidence; past approvals have led to price surges.

How important is it?

Approval marks a critical step towards commercialization, impacting MGRM's growth potential.

Why Short Term?

Initial trials will likely affect stock price as investor sentiment builds.

Related Companies

SHALBY
Monogram Granted Regulatory Approval to Import mBôs TKA System for Clinical Investigation Patient Enrollment will Begin Shortly; First Live Patient Surgeries are Anticipated within 90 Business Days Critical Milestone Achieved for Multi-Center Clinical Trial in India with Strategic Partner Shalby Hospitals for the mBȏs TKA System AUSTIN, TX / ACCESS Newswire / April 29, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced it has obtained regulatory approval from India's Central Drugs Standard Control Organization ("CDSCO") to import its mBôs TKA system to conduct a 102-patient, multi-center clinical investigation evaluating the safety and effectiveness of the Monogram TKA System. The study will be conducted in collaboration with Shalby Limited (NSE: SHALBY) ("Shalby"), one of the world's largest orthopedic hospital groups.

Related News